Major Depressive Disorder: FDA Approves SPRAVATO®

The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray as the first and only treatment for adults with major depressive disorder (MDD) who have not responded to at least two oral antidepressants.

Major Depressive Disorder (MDD) is a debilitating mental health condition affecting over 21 million adults in the United States alone. Characterized by persistent feelings of sadness, hopelessness, and loss of interest, MDD significantly impacts daily life, relationships, and overall well-being. Despite the availability of numerous antidepressants, nearly one-third of MDD patients fail to respond to at least two oral antidepressants, leading to what is known as treatment-resistant depression (TRD).

Treatment-Resistant Depression (TRD)

TRD is a severe form of depression that does not improve with standard antidepressant therapy. Patients with TRD often experience prolonged suffering, a higher risk of suicide, and increased healthcare utilisation. The exact causes of TRD remain unclear, but experts believe it involves dysregulation of neurotransmitters, including serotonin, dopamine, and glutamate.

For years, treatment options for TRD were limited to:

• Switching to different antidepressants
• Augmenting therapy with antipsychotics
• Electroconvulsive therapy (ECT) for severe cases

However, these approaches often provided limited relief and came with significant side effects. The search for an effective alternative led researchers to explore the role of glutamate in mood disorders.

SPRAVATO® in TRD Treatment

In the latest advancement, SPRAVATO® (esketamine) CIII nasal spray has emerged as a revolutionary treatment for TRD. Initially approved in 2019 as an adjunct therapy, SPRAVATO® has now received FDA approval as the first treatment for adults with TRD. This approval marks a significant milestone, offering new hope to patients with limited options.

How Does SPRAVATO® Work?

Unlike traditional antidepressants that target serotonin and dopamine, SPRAVATO® modulates the glutamate system, which plays a crucial role in mood regulation and cognitive function. By working through the N-methyl-D-aspartate (NMDA) receptor, SPRAVATO® helps restore neural connections damaged by chronic depression, leading to faster symptom relief.

Clinical Evidence Supporting SPRAVATO®

FDA approval for SPRAVATO® as a monotherapy is based on rigorous clinical trials demonstrating its efficacy and safety. Key findings include:

• Rapid symptom improvement: Many patients experienced significant relief within 24 hours of the first dose.
• Higher remission rates: At week 4, 22.5% of SPRAVATO® patients achieved remission, compared to 7.6% in the placebo group.
• Sustained benefits: Continued use of SPRAVATO® helped maintain long-term symptom relief, reducing the likelihood of relapse.

How SPRAVATO® is Administered

SPRAVATO® is a nasal spray administered under the supervision of a healthcare provider. Due to its potential risks, it is available only through the Risk Evaluation and Mitigation Strategy (REMS) program. Key guidelines include:

• Patients must self-administer SPRAVATO® in a certified healthcare setting under medical supervision.
• Post-dose monitoring for at least two hours is required due to risks of dissociation, sedation, and increased blood pressure.
• Treatment typically involves twice-weekly doses for the first month, followed by maintenance dosing.

Safety Considerations and Side Effects

While SPRAVATO® offers promising results, it is important to understand potential risks, including:

• Common side effects: Dizziness, nausea, headache, increased blood pressure, and dissociation.
• Serious warnings: Risk of sedation, misuse, and respiratory depression. Patients with aneurysmal vascular disease or history of brain bleeding should not use SPRAVATO®.
• Controlled administration: To prevent misuse, it is not available for at-home use.

The Future of Depression Treatment

SPRAVATO®’s approval as a monotherapy marks a turning point in mental health treatment. By addressing TRD through a novel mechanism, it opens the door for future research into glutamate-targeting therapies. As more studies explore innovative treatments, the hope is to further reduce the burden of depression and improve mental well-being worldwide.

For individuals struggling with TRD, SPRAVATO® offers a new path to relief and recovery. If you or someone you know is dealing with treatment-resistant depression, consult a healthcare professional to explore available options.

When to Seek Immediate Medical Attention

Patients or their families should contact a healthcare provider or seek emergency help if they notice any of the following symptoms, especially if they are new, worsening, or concerning:

• Suicidal thoughts or behavior
• New or worsening depression or anxiety
• Panic attacks or extreme mood swings
• Manic episodes (increased activity and talking)Unusual changes in behavior or aggression
• Trouble sleeping (insomnia) or acting on dangerous impulses